用于治疗糖尿病男性勃起功能障碍的西尔德纳菲尔:随机对照试验. 西尔德纳菲尔糖尿病研究小组研究小组
M S Rendell1, J Rajfer, P A Wicker
1Creighton Diabetes Center, Omaha, Neb 68131, USA.
JAMA
|February 10, 1999
概括
西尔德纳菲尔有效地治疗糖尿病男性的勃起功能障碍. 这种口服药物改善了性交成功率,并且耐受性良好,常见的副作用包括头痛和消化不良.
科学领域:
- 泌尿器科 泌尿器科 泌尿器科 泌尿器科
- 内分泌学 在内分泌学.
- 药理学 药理学是指药理学的学科.
背景情况:
- 勃起功能障碍 (ED) 是被诊断为糖尿病的男性普遍出现的并发症.
- 由于血管和神经损伤,糖尿病会显著损害勃起功能.
研究的目的:
- 评估口服西尔代纳菲尔酸盐治疗勃起功能障碍 (ED) 的疗效和安全性,特别是在糖尿病男性群体中.
- 为了比较西尔代纳菲尔与安慰剂在改善勃起功能方面的有效性.
主要方法:
- 一个多中心的,随机的,双盲的,安慰剂控制的,灵活的剂量升级研究.
- 268名患有ED和糖尿病的男性随机分配给接受西尔代纳菲尔 (n=136) 或安慰剂 (n=132) 12周.
- 通过使用国际勃起功能指数来评估自我报告达到和维持勃起的能力来评估有效性.
主要成果:
- 与安慰剂相比,士迪纳菲尔显著改善了勃起功能,56%的患者报告勃起更好,而10% (P<.001).
- 顺利性交的尝试增加到西尔德纳菲尔组的61%,而安慰剂组的22% (P<.001).
- 与安慰剂 (1%) 相比,西尔代纳菲尔 (16%) 的不良事件更常见,主要是头痛,消化不良和呼吸系统问题;心血管事件在两组之间相似.
结论:
- 口服西尔代纳菲尔酸盐是糖尿病男性勃起功能障碍的安全有效治疗选择.
- 这种药物在这个患者群体中表现出良好的耐受性.
相关概念视频
Treatment for Pulmonary Arterial Hypertension: Phosphodiesterase Inhibitors
Phosphodiesterase 5 (PDE5) inhibitors are potent enzymes that function to hydrolyze cyclic nucleotides to their corresponding 5' monophosphates. Their unique biochemical properties have been applied in treating Pulmonary Arterial Hypertension (PAH).
Among the PDE5 inhibitors, sildenafil (Revatio) stands out as a competitive and selective inhibitor. It operates by elevating cellular levels of cGMP and augmenting signaling through the cGMP-PKG pathway, promoting vasodilation. Upon oral...
Among the PDE5 inhibitors, sildenafil (Revatio) stands out as a competitive and selective inhibitor. It operates by elevating cellular levels of cGMP and augmenting signaling through the cGMP-PKG pathway, promoting vasodilation. Upon oral...
Disorders of the Male Reproductive System
Men's health issues are increasingly recognized as significant, with several conditions posing common threats. Among these, testicular cancer is especially prevalent in younger men, particularly those aged 20 to 35 years. The disease often manifests as a painless mass in the testicles, sometimes accompanied by a sensation of heaviness or a dull ache.
Prostate disorders are another major concern. These conditions can impair urinary flow due to the prostate's location around the urethra. Symptoms...
Prostate disorders are another major concern. These conditions can impair urinary flow due to the prostate's location around the urethra. Symptoms...
Effect of Hepatic Disease on Pharmacokinetics: Dose Adjustments Due to Hepatic Impairment
Hepatic impairment, characterized by decreased liver function, does not uniformly mandate adjustments in drug dosage. Whether dosage modifications are necessary depends on various factors related to the drug's metabolism and elimination pathways. If a drug is primarily excreted via the kidneys and bypasses significant hepatic processing, if it undergoes minimal metabolic transformation in the liver, or if it is volatile and primarily expelled through the lungs, dose adjustments may not be...
Diabetes: Management and Pharmacotherapy
The therapy for diabetes aims to alleviate hyperglycemia-related symptoms, prevent acute metabolic decompensation, and reduce chronic end-organ complications. Glycemic control is evaluated through short-term (self-monitoring, continuous glucose monitoring) and long-term (A1c, fructosamine) metrics, enabling near real-time tracking of blood glucose levels and reflecting glycemic control over specific time frames.
Insulin remains the cornerstone of treatment for most patients with type 1 and many...
Insulin remains the cornerstone of treatment for most patients with type 1 and many...
Dipeptidyl Peptidase 4 Inhibitors
Dipeptidyl peptidase 4 (DPP-4) is a serine protease widely distributed in the body. It's involved in the inactivation of GLP-1 and GIP hormones, which are crucial for insulin regulation. DPP-4 inhibitors, such as sitagliptin (Januvia), saxagliptin (Onglyza), linagliptin (Tradjenta), alogliptin (Nesina), and vildagliptin (Galvus), help increase the proportion of active GLP-1, enhancing insulin secretion. These inhibitors work by competitively binding to DPP-4. This binding causes a significant...
Diabetic Retinopathy
DefinitionDiabetic retinopathy is a microvascular complication of diabetes affecting the retinal blood vessels.Risk FactorsDiabetic retinopathy is present in almost all individuals with type 1 diabetes and more than 60% of those with type 2 diabetes after two decades of disease.The risk increases with poor glycemic control, hypertension, dyslipidemia, smoking, pregnancy, and puberty.Although cataracts and glaucoma are also more frequent in people with diabetes, retinopathy remains the leading...

